Propofol has been suggested to have in vivo airway relaxant effects, although the mechanism is still unclear. In this study, we determined whether propofol could antagonize methacholineinduced bronchoconstriction and determined whether vagotomy modi®es this relaxant effect. Fourteen mongrel dogs anaesthetized with pentobarbital and pancuronium were assigned to a control group (n=7) and a vagotomy group (n=7). The trachea was intubated with a special endotracheal tube that had a second lumen for insertion of the bronchoscope. Bronchial crosssectional area, which was monitored continuously through the bronchoscope, was measured with image analysis software. Bronchoconstriction was elicited with methacholine (0.5 mg kg ±1 + 5.0 mg kg ±1 min
Propofol may produce anticholinergic effects on the airway as clinically it has been reported to prevent bronchospasm produced by tracheal intubation or fentanyl administration compared with thiopental in patients either with or without asthma 1±3 and produce bronchodilation in chronic obstructive pulmonary disease patients under mechanical ventilation. 4 In addition, using mongrel dogs, we previously reported that propofol decreased basal airway tone similarly to atropine and attenuated histamine-induced bronchoconstriction, and that this relaxant effect may be due to a reduction in vagal tone. 5 On the other hand, in vitro studies suggest direct relaxant effects of propofol on airway smooth muscles. The mechanism has been suggested to be through reduction in intracellular Ca 2+ concentration by block of L-type voltagesensitive Ca 2+ channels 6 and inhibition of Ca 2+ release from intracellular stores, 7 but not by decreased Ca 2+ sensitivity. 8 Similarly, volatile anaesthetic agents have also been reported to produce airway relaxation by vagolysis and more direct actions. 9 10 Regarding the neural mechanism, several reports 9 10 suggest that inhibition of the peripheral vagal motor pathway may be involved. Muscarinic receptors play an important role in cholinergic effects on the airway, 11 and previous reports suggest that muscarinic receptor subtypes m1, m2 and m3 exist in the human airway. 12 The m1 receptors facilitate neurotransmission through parasympathetic ganglia and enhance cholinergic re¯exes. Activation of m3 receptors produces contraction of airway smooth muscles. Activation of m2 receptors inhibits the release of acetylcholine and may also counteract the bronchodilation produced by b-agonists. 12 Methacholine is a nonselective muscarinic receptor agonist, 13 and has been used clinically to quantitate airway responsiveness in asthmatic patients. 14 In this study, we determined whether propofol could antagonize the muscarinic receptor-activated bronchoconstriction induced by methacholine. In addition, we compared the relaxant effects in normal dogs with those in vagotomized dogs to determine whether the relaxant effects are centrally mediated.
LABORATORY INVESTIGATION

Methods
Our study protocol was approved by the Animal Care and Use Committee of the University of Hirosaki School of Medicine. Fourteen mongrel dogs (8±12 kg) were anaesthetized with i.v. pentobarbital (30 mg kg ±1 + 2.0 mg kg ±1 h ±1 ) and assigned to a control group (n=7) or a vagotomy group (n=7). The tracheas were intubated with endotracheal tubes (internal diameter 7.0 mm; Univent Tube, Fuji System, Tokyo, Japan) that had a second lumen for the insertion of a super®ne ®bre-optic bronchoscope. Neuromuscular block was obtained with pancuronium 0.2 mg kg ±1 h ±1 for mechanical ventilation with oxygen using a volume-controlled respirator (Servo 900C), and end-tidal carbon dioxidewas maintained at 4.0±4.5%. The femoral artery was cannulated to monitor arterial blood pressure and for blood sampling. The femoral vein was also cannulated for the insertion of a double lumen catheter, through which¯uid and drugs were administered. In the vagotomy group, the vagus nerves were isolated and then cut bilaterally.
The cross-sectional area of third bronchial bifurcation in the right lung was monitored via a super®ne ®bre-optic bronchoscope (outside diameter 2.2 mm, AF type 22A; Olympus, Tokyo, Japan) to assess bronchial tone, as reported previously.
5 15±18 Brie¯y, the image of the third bifurcation was printed with a video printer (VY-170; Hitachi, Tokyo, Japan) during the end-expiratory pause, and was then loaded into a Macintosh computer (Power Macintosh 7100/80 AV, Apple Computer, CA, USA) via a scanner (Scan-Jet 4c; Hewlett Packard, CO, USA) to measure bronchial cross-sectional area with image analysis software (MacScope 2.56; Mitani, Fukui, Japan). Image processing was performed by an investigator who was blinded to the study protocol.
Bronchoconstriction was elicited by i.v. infusion of methacholine (0.5 mg kg ±1 + 5 mg kg ±1 min ±1 ) until the end of the experiment. Initially we con®rmed that this bronchoconstriction could be fully reversed by atropine. Thirty minutes after the start of methacholine infusion, the following doses of propofol were given at 10 min intervals in the order indicated: 0 (saline), 0.2, 2.0, 20 mg kg ±1 . Bronchial cross-sectional area was measured before and 30 min after methacholine infusion started and 5 min after each propofol dose. Bronchial cross-sectional areas are presented as percentages of basal.
Arterial blood samples (6 ml) were centrifuged immediately at 3000 r.p.m. for 10 min at ±10°C to separate plasma, which was then frozen at ±70°C until measurement of catecholamines and propofol concentrations by high-performance liquid chromatography. 19 20 The lower detection limits were 15 pg ml ±1 for norepinephrine, 20 pg ml ±1 for epinephrine and 100 ng ml ±1 for propofol. The intra-assay coef®cient of variation was 3.3% for norepinephrine, 6.0% for epinephrine and 2.9% for propofol. 
Statistical analysis
All data are expressed as mean (95% con®dence interval). Data were analysed by repeated measures analysis of variance followed by Fisher's protected least signi®cant difference test using StatView II on a Macintosh computer. P<0.05 was considered signi®cant. To obtain a concentration±response curve for propofol-induced relaxation, relaxation was expressed as a percentage: peak constriction by methacholine=0% and full relaxation (baseline)=100%. The sigmoid concentration±response curve was ®tted using GraphPad Prism 1.03, and the maximal inhibition and ±log of the concentration (mM) producing 50% inhibition of maximal effect (pIC 50 ) of propofol were obtained from each concentration±response curve. Methacholine decreased the bronchial cross-sectional area to 49.3 (38.5±60.1) and 45.3 (34.8±55.7)% of the basal bronchial cross-sectional area in the control and vagotomy groups respectively. In the control group, propofol 2.0 and 20 mg kg ±1 signi®cantly increased bronchial cross-sectional area, to 61.2 (49.4±73.1) and 77.8 (66.2±89.6)% of basal respectively (Fig. 1A) . Similarly, in the vagotomy group the bronchial cross-sectional area was signi®cantly increased to 75.9 (64.0±87.9)% of basal after propofol 20 mg kg ±1 but not signi®cantly after 2.0 mg kg ±1 (Fig. 1A) . Maximal inhibition of methacholine-induced bronchoconstriction by propofol in the control and vagotomy groups, from the sigmoid concentration±response curve of propofol-induced relaxation, was 61.1 (46.3±76.9) and 64.2 (40.1±88.3)% respectively. The pIC 50 of propofol in the control and vagotomy groups was 5.03 (4.55±5.51) (mean 9.3 mM) and 4.86 (4.49±5.24) (13.8 mM) respectively. There were no signi®cant differences in maximal inhibition and IC 50 between groups (Fig. 1B) .
Results
Plasma
Plasma catecholamine concentration was signi®cantly reduced after propofol 20 mg kg ±1 i.v. in both groups, and the reduction in plasma catecholamines did not differ between groups (Table 1) .
Discussion
We have reported previously that the relaxant effect of propofol may be due to vagolysis. 5 In the present study, as the spasmolytic effects of propofol did not differ between vagotomized and intact dogs, the spasmolytic effects of propofol on methacholine-induced bronchoconstriction may not be mediated centrally. Therefore, the relaxation could be due to inhibition of the peripheral vagal motor pathway or to direct inhibition. In addition, Brown and Wagner 21 reported that bronchoprotective effects of propofol in vivo as a local infusion via the bronchial artery attenuated vagal nerve stimulation-induced bronchoconstriction. Figure 1B shows that the in vivo relaxant effect of propofol is concentration-dependent, and the clinical concentration (about 30 mM) 22 may reverse methacholineinduced bronchoconstriction by 45%. Azizkhan and colleagues 23 reported that tracheal cross-sectional area in respiratory symptomatic paediatric patients with a mediastinal mass was decreased by 35±93% of the normal tracheal dimensions. Huysmans and colleagues 24 studied the effectiveness of radioiodine therapy in patients with a large goitre compressing the trachea. They found that the tracheal crosssectional area of the smallest lumen increased by 36% after therapy, and clinical symptoms such as dyspnoea and inspiratory stridor improved in eight of 12 patients. Therefore, 45% relaxation by clinical concentrations of propofol in the present study may be clinically signi®cant.
In this study, propofol 2 mg kg ±1 signi®cantly reversed bronchoconstriction in the control group, but the reversal effect was not signi®cant in the vagotomy group. However, plasma propofol concentration after 2 mg kg ±1 i.v. was signi®cantly higher in the control group than in the vagotomy group. In addition, as described above, there were no signi®cant differences between the groups in Direct relaxant effects of propofol should also be considered. As methacholine predominantly activates muscarinic receptors rather than nicotinic receptors, it is possible that propofol inhibits muscarinic receptor responses directly. Similarly, we reported previously that propofol concentration-dependently shifts the concentration±response curve of carbachol-induced contraction of guinea-pig tracheal smooth muscle. 25 However, using a radioligand binding assay, Lin and colleagues 7 reported that propofol (<100 mM) may not interact with muscarinic receptors in airway smooth muscles, although propofol 300 mM signi®cantly decreased the binding af®nity of [
3 H]N-methyl-scopolamine to muscarinic receptors. It was also reported that propofol reduced the intracellular Ca 2+ concentration in airway smooth muscle cells by inhibition of Ca 2+ in¯ux and of Ca 2+ release from internal stores. Similarly, Yamakage and colleagues 6 showed that more than 10 mM of propofol signi®cantly reduced Ca 2+ current through voltage-sensitive Ca 2+ channels in the airway smooth muscle cells. These data suggest that inhibition of Ca 2+ mobilization by propofol may be involved in the direct relaxant effects.
Pancuronium was infused to prevent spontaneous respiration and bucking in the present study. As pancuronium has been reported to inhibit m2 rather than m1 or m3 receptors, 26 pancuronium may antagonize activation of m2 receptors by methacholine. Although m2 activation causes a reduction in acetylcholine release, the main mechanism of methacholine-induced bronchoconstriction is via m3 activation. In addition, although m2 receptors also counteract b-agonist-induced relaxation, propofol reduced plasma epinephrine concentrations in the present study. Therefore, pancuronium infusion may not attenuate methacholineinduced bronchoconstriction.
In the present study, plasma catecholamines were signi®cantly reduced by propofol. This is consistent with a previous paper which showed that propofol produces sympatholysis more potently than vagolysis. 27 As the direct neural supply of the sympathetic system is limited in the lung, sympathetic in¯uence on the airway tone is dependent on the plasma concentration of catecholamines. 28 Therefore, plasma catecholamines, especially epinephrine, may modulate airway smooth muscle tone. Indeed, we observed previously that histamine-induced bronchoconstriction was worsened by phenylephrine 16 and lidocaine, 17 with a reduction in plasma catecholamines, and reversed by droperidol 15 and divalent cations (Mg 2+ and Zn 2+ ) 18 with an increase in plasma catecholamines. Therefore, the decrease in plasma catecholamines may partially antagonize the relaxant effects of propofol.
In conclusion, the present data suggest that propofol inhibits methacholine-induced bronchoconstriction, but relaxation is not mediated via a central vagal pathway. This result is consistent with clinical reports suggesting potential bronchoprotective effects of propofol. However, it remains to be determined whether the relaxant effects are mediated through the peripheral vagal motor pathway or via direct actions.
